Results 41 to 50 of about 13,799 (205)

Perspectives and practices of ototoxicity monitoring

South African Journal of Communication Disorders, 2020
Background: Treatment of cancer with cisplatin can result in hearing loss. Given the increasing burden of cancer in Africa, appropriate and timely identification, intervention and management of hearing loss in affected patients is of paramount importance.
Jessica Paken, Cyril D. Govender, Mershen Pillay, Vikash Sewram   +3 more
doaj   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Glutathione carbon dots as an intracellular reactive oxygen species scavenger for reducing cisplatin‐induced ototoxicity

View
It is widely recognized that platinum‐based chemotherapy, particularly cisplatin therapy, can cause ototoxicity. At present, there are no Food and Drug Administration‐approved drugs to prevent or alleviate ototoxicity.
Yaqin Tu, Guorun Fan, Nan Wu, Bo Liu, Haiying Sun, Qiong Wang, Wenqing Zou, Hongjun Xiao, Songwei Tan   +8 more
doaj   +1 more source

Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review

Frontiers in Cellular Neuroscience, 2023
Cisplatin is a first-line chemotherapeutic agent in the treatment of malignant tumors with remarkable clinical effects and low cost. However, the ototoxicity and neurotoxicity of cisplatin greatly limit its clinical application.
Yingru Li, Yingru Li, Yingru Li, Tianyang Zhang, Tianyang Zhang, Tianyang Zhang, Qiang Song, Qiang Song, Qiang Song, Dekun Gao, Dekun Gao, Dekun Gao, Yue Li, Yue Li, Yue Li, Huiqun Jie, Huiqun Jie, Huiqun Jie, Ping Huang, Ping Huang, Ping Huang, Guiliang Zheng, Guiliang Zheng, Guiliang Zheng, Jun Yang, Jun Yang, Jun Yang, Jingchun He, Jingchun He, Jingchun He   +29 more
doaj   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

Current Strategies to Combat Cisplatin-Induced Ototoxicity

Frontiers in Pharmacology, 2020
Cisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated.
Dehong Yu, Dehong Yu, Dehong Yu, Jiayi Gu, Jiayi Gu, Jiayi Gu, Yuming Chen, Yuming Chen, Yuming Chen, Wen Kang, Wen Kang, Wen Kang, Xueling Wang, Xueling Wang, Xueling Wang, Hao Wu, Hao Wu, Hao Wu   +17 more
doaj   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source

Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children

British Journal of Clinical Pharmacology, EarlyView.
Codeine is commonly used in combination analgesic products. The use of codeine during breastfeeding can rarely be associated with serious adverse effects related to genetic polymorphisms affecting codeine's metabolism and disposition. Clinicians treating infants of breastfeeding mothers should be aware of this rare but potentially serious complication.
Michael Rieder
wiley   +1 more source

Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions

B-ENT, 2014
Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions. Objective: Pure tone audiometry (PTA) is currently widely used to monitor ototoxicity, but this method is timeconsuming.
M. K. Md Daud, H. Mohamad, A. Haron, N. A. Rahman   +3 more
doaj   +2 more sources

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott, Sian Hilton, Cinzia Dello Russo, Nicola Booth, Simon Drysdale, Philip Howard, Stephen Hughes, Mallinath Chakraborty, Helen McDevitt, Charlotte Alston, Maya Desai, Mike Beadsworth, Adam Reynolds, Serim Min, Katherine Payne, Munir Pirmohamed, William G. Newman   +16 more
wiley   +1 more source